Investment
Features
FeesSafety
Academy
More
Pluang+

Compare USA Rare Earth Inc. Class A Common Stock (USAR) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

USA Rare Earth Inc. Class A Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

USA Rare Earth Inc. Class A Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? USA Rare Earth Inc. Class A Common Stock trades at $10.14 (market cap $4.23B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: USA Rare Earth Inc. Class A Common Stock is far larger — about 2.4× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold USA Rare Earth Inc. Class A Common Stock for 0 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

USARVIR
Market Cap
$4.23B$1.80B
Volume
13,677,6601,782,836
Sector
Basic MaterialsHealth
52-Week High
$33.68$11.78
52-Week Low
$10.32$5.12
Typical Hold Time
0 Days0 Days
Enterprise Value
$2.70B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

USA Rare Earth Inc. Class A Common Stock

USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.

The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

USAR
100% Buy0% Sell
Avg holding period · 0 Days
VIR
51% Buy49% Sell
Avg holding period · 0 Days

About USA Rare Earth Inc. Class A Common Stock

USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.

Read more on USAR →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →